Clinical Trials
3 trialsNCT06027268 2026-04-22
ToPCourT
Wake Forest University Health Sciences
Phase 2 Active not recruiting
NCT04863248 2023-04-14
PRESERVE 4
G1 Therapeutics, Inc.
Phase 2 Terminated
NCT02978716 2022-03-23
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
G1 Therapeutics, Inc.
Phase 2 Terminated